RP Bio Inc. (KOSDAQ:314140)
South Korea
· Delayed Price · Currency is KRW 5,890.00
+10.00 (0.17%)
Last updated: Aug 8, 2025
RP Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Operating Revenue | 125,470 | 123,967 | 151,046 | 138,109 | 114,964 | 97,923 | Upgrade
|
| Other Revenue | - | - | -0 | -0 | -0 | - | Upgrade
|
| Revenue | 125,470 | 123,967 | 151,046 | 138,109 | 114,964 | 97,923 | Upgrade
|
| Revenue Growth (YoY) | -15.24% | -17.93% | 9.37% | 20.13% | 17.40% | 40.18% | Upgrade
|
| Cost of Revenue | 116,196 | 116,783 | 135,487 | 120,355 | 102,052 | 85,305 | Upgrade
|
| Gross Profit | 9,275 | 7,184 | 15,560 | 17,754 | 12,912 | 12,617 | Upgrade
|
| Selling, General & Admin | 6,542 | 6,509 | 7,678 | 7,109 | 6,036 | 7,167 | Upgrade
|
| Research & Development | - | - | - | - | - | 36.49 | Upgrade
|
| Other Operating Expenses | 522.79 | 538.68 | 533.92 | 447.05 | 410.13 | 378.38 | Upgrade
|
| Operating Expenses | 7,902 | 7,878 | 8,937 | 8,107 | 7,032 | 8,460 | Upgrade
|
| Operating Income | 1,373 | -693.64 | 6,623 | 9,647 | 5,880 | 4,157 | Upgrade
|
| Interest Expense | -1,188 | -1,251 | -1,796 | -1,184 | -979.22 | -1,123 | Upgrade
|
| Interest & Investment Income | 588.87 | 521.51 | 703.69 | 316.79 | 165.63 | 159.56 | Upgrade
|
| Currency Exchange Gain (Loss) | -7.17 | -1.04 | -11.69 | -29.51 | -1.84 | -7.48 | Upgrade
|
| Other Non Operating Income (Expenses) | 219.62 | 216.48 | 198.12 | -3,232 | -769.29 | 1,019 | Upgrade
|
| EBT Excluding Unusual Items | 986.18 | -1,208 | 5,717 | 5,519 | 4,295 | 4,205 | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.12 | -9.24 | -59.74 | 150.06 | -4.31 | 4.68 | Upgrade
|
| Pretax Income | 988.3 | -1,217 | 5,658 | 5,669 | 4,291 | 4,209 | Upgrade
|
| Income Tax Expense | -318.76 | -309.88 | 220.38 | 1,353 | 478.26 | -406.11 | Upgrade
|
| Net Income | 1,307 | -907.12 | 5,437 | 4,316 | 3,813 | 4,616 | Upgrade
|
| Net Income to Common | 1,307 | -907.12 | 5,437 | 4,316 | 3,813 | 4,616 | Upgrade
|
| Net Income Growth | -70.08% | - | 25.99% | 13.20% | -17.40% | 61.13% | Upgrade
|
| Shares Outstanding (Basic) | 9 | 9 | 9 | 7 | 7 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 9 | 9 | 7 | 7 | 7 | Upgrade
|
| Shares Change (YoY) | -21.14% | -7.41% | 31.19% | 8.34% | -1.16% | 1.46% | Upgrade
|
| EPS (Basic) | 151.04 | -104.87 | 630.00 | 617.00 | 580.00 | 702.00 | Upgrade
|
| EPS (Diluted) | 151.04 | -104.87 | 582.00 | 606.00 | 580.00 | 694.00 | Upgrade
|
| EPS Growth | -62.06% | - | -3.96% | 4.48% | -16.43% | 58.81% | Upgrade
|
| Free Cash Flow | 9,175 | 7,670 | -543.31 | -3,992 | 2,213 | -5,006 | Upgrade
|
| Free Cash Flow Per Share | 1060.30 | 886.77 | -58.16 | -560.54 | 336.69 | -752.72 | Upgrade
|
| Gross Margin | 7.39% | 5.79% | 10.30% | 12.86% | 11.23% | 12.88% | Upgrade
|
| Operating Margin | 1.09% | -0.56% | 4.38% | 6.98% | 5.12% | 4.25% | Upgrade
|
| Profit Margin | 1.04% | -0.73% | 3.60% | 3.13% | 3.32% | 4.71% | Upgrade
|
| Free Cash Flow Margin | 7.31% | 6.19% | -0.36% | -2.89% | 1.93% | -5.11% | Upgrade
|
| EBITDA | 8,197 | 6,124 | 12,671 | 15,050 | 11,083 | 8,571 | Upgrade
|
| EBITDA Margin | 6.53% | 4.94% | 8.39% | 10.90% | 9.64% | 8.75% | Upgrade
|
| D&A For EBITDA | 6,823 | 6,818 | 6,048 | 5,403 | 5,203 | 4,414 | Upgrade
|
| EBIT | 1,373 | -693.64 | 6,623 | 9,647 | 5,880 | 4,157 | Upgrade
|
| EBIT Margin | 1.09% | -0.56% | 4.38% | 6.98% | 5.12% | 4.25% | Upgrade
|
| Effective Tax Rate | - | - | 3.90% | 23.87% | 11.15% | - | Upgrade
|
| Advertising Expenses | - | 80.7 | 225.5 | 230.56 | 135.92 | 144.6 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.